Based in the United States, Viridian Therapeutics, Inc. is a pharmaceutical company specializing in the development of treatments for thyroid eye disease. With a medium risk rating score of 28.8, Viridian Therapeutics focuses on creating innovative product candidates, such as VRDN-001, an insulin-like growth factor-1 receptor monoclonal antibody. This clinical-stage biopharmaceutical company prioritizes sustainability and governance in its operations, making it a promising player in the ESG-driven pharmaceutical industry.